Research Article

Insulin Resistance Associated with Plasma Xanthine Oxidoreductase Activity Independent of Visceral Adiposity and Adiponectin Level: MedCity21 Health Examination Registry

Masafumi Kurajoh,1 Shinya Fukumoto,2 Takayo Murase,3 Takashi Nakamura,3 Takuma Ishihara,4 Hiromi Go,5,6 Kouji Yamamoto,5,6 Shinya Nakatani,1 Akihiko Tsuda,1 Tomoaki Morioka,5,6 Katsuhiro Mori,7 Yasuo Imanishi,1 Masaaki Inaba,1,7 and Masanori Emoto1

1Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan
2Department of Premier Preventive Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan
3Mie Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd., Inabe, Mie, Japan
4Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Japan
5Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan
6Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan
7Department of Nephrology, Osaka City University Graduate School of Medicine, Osaka, Japan

Correspondence should be addressed to Masafumi Kurajoh; m1155129@med.osaka-cu.ac.jp

Received 25 September 2019; Revised 12 November 2019; Accepted 11 December 2019; Published 30 December 2019

Academic Editor: Claudio Casella

Copyright © 2019 Masafumi Kurajoh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Higher levels of uric acid production have been reported in individuals with visceral fat obesity, and obesity is known to enhance xanthine oxidoreductase (XOR) activity, although the precise mechanism remains unclear. We investigated the associations of visceral fat area (VFA), serum adiponectin level, and insulin resistance with plasma XOR activity using our novel highly sensitive assay based on [13C2,15N2] xanthine and liquid chromatography/triple quadrupole mass spectrometry.

Methods. This cross-sectional study included 193 subjects (92 males and 101 females) registered in the MedCity21 health examination registry. Plasma XOR activity, serum adiponectin level, and VFA obtained by computed tomography were measured, and insulin resistance was determined based on the homeostasis model assessment (HOMA-IR) index. The mean values for VFA, log HOMA-IR, and log plasma XOR activity were 76.8 ± 45.8 cm², 0.14 ± 0.30, and 1.50 ± 0.44 pmol/h/mL, respectively. Multiple regression analysis showed that HOMA-IR was significantly (p = 0.020) associated with plasma XOR activity independent of other factors, including VFA and adiponectin level, as well as age, sex, alcohol drinking habit, smoking habit, alanine transaminase, HbA1c, and eGFR. The “sex*HOMA – IR” interaction was not significant (p = 0.89), indicating that sex difference does not have an effect on the relationship between HOMA-IR and plasma XOR activity. Conclusions. Our results indicate that insulin resistance is associated with plasma XOR activity and that relationship is independent of visceral adiposity and adiponectin level, suggesting that the development of insulin resistance resulting from increased visceral adiposity and/or reduced serum adiponectin contributes to increased uric acid production by stimulating XOR activity.
1. Introduction

Hyperuricemia is frequently complicated with obesity in individuals with visceral fat accumulation [1, 2], which is strongly associated with insulin resistance [3]. In affected patients, hyperuricemia is considered to be caused by reduced renal excretion of uric acid as a consequence of insulin-mediated renal reabsorption of uric acid in the proximal tubules, as a result of insulin resistance [4]. However, previous studies have emphasized that individuals with visceral fat obesity also have increased production of uric acid [2, 5].

Xanthine oxidoreductase (XOR) is a rate-limiting enzyme for in vivo uric acid production that catalyzes oxidation not only from hypoxanthine to xanthine but also from xanthine to uric acid in the purine metabolism pathway [6]. In humans, XOR is exclusively expressed in the liver and intestines but not in adipose tissue [7, 8]; thus, elevated plasma XOR activity in obese subjects can be explained by increased XOR activity in the liver and intestines but not in adipose tissue [9, 10]. Furthermore, those reports suggested that visceral fat accumulation might indirectly contribute to increased XOR activity preferentially in the liver but not intestines, resulting in overproduction of uric acid, although the precise mechanism remains unclear. Of importance, some studies have shown an association of insulin resistance with plasma XOR activity in young healthy subjects, a general population cohort, and subjects with familial combined hyperlipidemia [11–13].

To the best of our knowledge, no studies have examined the association of insulin resistance with plasma XOR activity together with adiposity and adipocytokines. The purpose of the present study was to examine the associations of visceral fat area (VFA), obtained by computed tomography (CT), as well as serum adiponectin level and insulin resistance, assessed by homeostatic model assessment of insulin resistance (HOMA-IR), a reliable surrogate marker for insulin resistance [14, 15], with plasma XOR activity using our newly developed assay for determining XOR activity [16, 17] in subjects who participated in the MedCity21 health examination registry.

2. Materials and Methods

2.1. Study Design. The MedCity21 health examination registry was instituted from April 2015 in a comprehensive manner to elucidate the causes of various diseases occurring in adults (cancer, diabetes mellitus (DM), cardiovascular disease, cerebrovascular disease, mental disorders, dyslipidemia, hypertension, hyperuricemia, obesity, chronic respiratory disease, liver disease, digestive disease, gynecological diseases, skin disease, etc.) for the development of advanced diagnostic techniques, treatment methods, and prevention methods for patients with those diseases [18–20]. Individuals who underwent comprehensive medical examinations at MedCity21 at the Osaka City University Hospital Advanced Medical Center for Preventive Medicine (Osaka, Japan) were registered. The MedCity21 health examination registry protocol was approved by the Ethics Committee of Osaka City University Graduate School of Medicine (approval No. 2927). Written informed consent was obtained from all subjects, and the study was conducted in full accordance with the Declaration of Helsinki. The present study protocol was approved by the Ethics Committee of Osaka City University Graduate School of Medicine (approval No. 3684) and performed with an opt out option, explained in instructions on the website of the hospital. Using findings presented in the MedCity21 health examination registry, we previously reported the association of plasma XOR activity with serum uric acid level [18]. In the present study, some of the methods used were the same as in that investigation and have reproduced relevant descriptions from that prior report in the present text.

2.2. Participants. Using the MedCity21 health examination registry, the final 200 sequential participants who participated in the lifestyle course of the advanced comprehensive medical examination, which was designed to check the status of lifestyle-related diseases, such as hypertension, diabetes, dyslipidemia, visceral obesity, hyperuricemia, atherosclerosis, and cerebrovascular disease, were selected. For our analysis, participants being treated with a xanthine oxidoreductase inhibitor (n = 4), or uricosuric (n = 1) or insulin (n = 1) agents, or with missing data (n = 1) were excluded. As a result, 193 participants were enrolled as subjects in the present cross-sectional study.

2.3. Physical and Laboratory Measurements. Information regarding height, body weight, smoking, and alcohol consumption habits, present and past illness, and use of medication was obtained. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters (kg/m²). DM was diagnosed when fasting plasma glucose was ≥126 mg/dl or 2-hour plasma glucose during a 75 g oral glucose tolerance test was ≥200 mg/dl, glycated hemoglobin A1c was ≥6.5%, or previous therapy for DM had been received [21]. Hypertension was defined as systolic blood pressure of ≥140 mmHg, diastolic blood pressure of ≥90 mmHg, or treatment for hypertension [22]. Dyslipidemia was defined as low-density lipoprotein cholesterol of ≥140 mg/dl, high-density lipoprotein cholesterol of ≤40 mg/dl, triglycerides of ≥150 mg/dl, or treatment for dyslipidemia [23]. Blood was drawn after an overnight fast. Biochemical parameters were analyzed using a standard laboratory method, and the remaining blood samples were stored at −80°C. Serum creatinine was measured using an enzymatic method. Estimated glomerular filtration rate (eGFR) was calculated using an equation designed for Japanese subjects, as previously described [24]. Glycated hemoglobin A1c (HbA1c) levels were estimated as National Glycohemoglobin Standardization Program equivalent values (%) using the conversion formula established by the Japan Diabetes Society.
plasma were purified using a Sephadex G25 column, then previously described [16, 17]. Briefly, 100 μL aliquots of plasma were examined for the amount of [13C2,15N2] uric acid produced, which was calculated using a calibration curve, with XOR activities expressed as that amount (pmol/h/mL).

2.4. Measurement of Visceral and Subcutaneous Fat Areas. Using abdominal CT (Supria Grande, Hitachi, Ltd., Tokyo, Japan), we acquired a single 5 mm slice at the level of the umbilicus, as we previously described [18]. VFA and subcutaneous fat area (SFA) were automatically segmented, while VFA and SFA values were also automatically calculated using the fatPointer software package, ver.2 (Hitachi, Ltd., Tokyo, Japan). According to the manufacturer of this system, when using the same CT image, the reproducibility of both VFA and SFA measurements are 100%.

2.5. Plasma XOR Activity. Freshly frozen samples maintained at −80°C until the time of the assay were used to determine plasma XOR activity with the recently established method for assays of stable isotope-labeled [13C2,15N2] xanthine with liquid chromatography (LC)/triple quadrupole mass spectrometry (TQMS), as we previously described [16, 17]. Briefly, 100 μL aliquots of plasma were purified using a Sephadex G25 column, then mixed with Tris buffer (pH 8.5) containing [13C2,15N2] xanthine as a substrate, nicotinamide adenine dinucleotide−, and [13C6,15N3] uric acid as an internal standard, with the mixtures then incubated at 37°C for 90 minutes. Subsequently, they were combined with methanol (500 μL) and centrifuged at 2000 × g for 15 minutes at 4°C. Supernatants were collected, transferred to new tubes, and dried using a centrifugal evaporator. The residues were reconstituted in 150 μL of distilled water and filtered through an ultrafiltration membrane, then measurements were performed using LC/TQMS. Calibration standard samples were examined for the amount of [13C2,15N2] uric acid produced, which was calculated using a calibration curve, with XOR activities expressed as that amount (pmol/h/mL).

2.6. Statistical Analysis. For statistical analysis, serum adiponectin, IRI, HOMA-IR, and plasma XOR activity were logarithm-transformed (log) to follow a normal distribution. Multiple regression analyses were performed to determine whether HOMA-IR was independently associated with plasma XOR activity after adjustment using various clinical parameters, including VFA and adiponectin level. We did not select serum uric acid level as a covariate because uric acid is produced from xanthine by an XOR-catalyzed reaction. The nonlinearity of the effects of VFA, adiponectin, and HOMA-IR was included in the regression model because significant nonlinearity was detected in these associations with plasma XOR activity. In addition, we incorporated a 2-factor interaction term (sex×HOMA – IR) to assess the effect of sex difference on the relationship between HOMA-IR and plasma XOR activity. Variance inflation factor (VIF) was calculated to estimate the multicollinearity of each predictor. The reliability of the final regression model was internally validated using the bootstrap method. One hundred fifty sets of bootstrap samples were generated by resampling the original data, and the amount of optimism was estimated to determine the degree of overfitting. The R software package (version 3.2.2, R Foundation for Statistical Computing, Vienna, Austria) and Statistical Package for the Social Sciences software package (PASW Statistics, version 22.0) were used for data analysis. All reported p values are 2 tailed and were considered to indicate statistical significance at p < 0.05.

3. Results

3.1. Clinical Characteristics of Subjects. The characteristics of the enrolled subjects are shown in Table 1. The mean values for age, alanine aminotransferase (ALT), eGFR, uric acid, and HbA1c were 56.8 ± 12.7 years, 20.8 ± 11.7 U/L, 76.8 ± 14.2 mL/min/1.73 m², 5.5 ± 1.3 mg/dL, and 5.8 ± 0.5%, respectively, while those for VFA, log HOMA-IR, and log plasma XOR activity were 76.8 ± 45.8 cm², 0.14 ± 0.30, and 1.50 ± 0.44 pmol/h/mL, respectively. The number of subjects with DM, hypertension, and dyslipidemia were 25, 55, and 90, respectively, and the number of subjects receiving medication for DM, hypertension, and dyslipidemia were 6, 35, and 29, respectively.

3.2. Association of HOMA-IR with Plasma XOR Activity Independent of Clinical Factors including Adiposity and Adiponectin. To examine whether HOMA-IR is independently associated with plasma XOR activity after adjustment for other confounding factors, including age, sex, alcohol drinking habit, smoking habit, ALT, HbA1c, eGFR, VFA, and adiponectin as covariates, multiple regression analyses were performed (Table 2). HOMA-IR, but not VFA or adiponectin, was significantly and independently associated with plasma XOR activity (Table 2; Figures 1–3). The “sex×HOMA – IR” interaction was not significant (p = 0.89), providing no evidence that sex difference has an effect on the relationship between HOMA-IR and plasma XOR activity. Sex and HbA1c, as well as ALT, were significantly associated with plasma XOR activity (Figure 4). Furthermore, the regression model was internally validated and the estimated optimism level was 0.042, indicating no evidence of overfitting. When VFA was replaced with VFA and SFA or BMI, the independent association of HOMA-IR, and no association of VFA and SFA or BMI, with plasma XOR activity was retained (Tables 3 and 4). The VIF value for each predictor was less than 5, indicating no multicollinearity between the variables (Tables 2–4). Also, when ALT was replaced with AST, similar results were obtained (data not shown).
Table 1: Clinical characteristics of subjects (n = 193).

| Variable                  | Mean ± SD or n (%) |
|---------------------------|-------------------|
| Age, years                | 56.8 ± 12.7       |
| Males, n                  | 92 (47.7%)        |
| Alcohol drinking habit, n | 63 (32.6%)        |
| Smoking habit, n          | 39 (20.1%)        |
| DM, n                     | 25 (13.0%)        |
| Hypertension, n           | 55 (28.5%)        |
| Dyslipidemia, n           | 90 (46.6%)        |
| Total bilirubin, mg/dL    | 0.7 ± 0.3         |
| AST, U/L                  | 22.6 ± 8.2        |
| ALT, U/L                  | 20.8 ± 11.7       |
| eGFR, ml/min/1.73 m²      | 76.8 ± 14.2       |
| Uric acid, mg/dL          | 5.5 ± 1.3         |
| Fasting plasma glucose, mg/dL | 103.4 ± 15.5 |
| HbA1c, %                  | 5.8 ± 0.5         |
| BMI, kg/m²                | 22.9 ± 3.5        |
| VFA, cm²                  | 76.8 ± 45.8       |
| SFA, cm²                  | 141.4 ± 70.6      |
| Log [adiponectin, μg/mL]  | 0.94 ± 0.20       |
| Log [IRI, μU/mL]          | 0.74 ± 0.27       |
| Log [HOMA-IR]             | 0.14 ± 0.30       |
| Log [XOR activity, pmol/h/mL] | 1.50 ± 0.44 |

Data are presented as the mean ± standard deviation or n (%) for dichotomous variables. Adiponectin, IRI, HOMA-IR, and XOR activity were log-transformed (Log) to achieve a normal distribution. Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; BMI, body mass index; VFA, visceral fat area; SFA, subcutaneous fat area; IRI, immunoreactive insulin; HOMA-IR, homeostatic model assessment of insulin resistance; XOR, xanthine oxidoreductase.

4. Discussion

Findings in the present study demonstrated that HOMA-IR, but not VFA or serum adiponectin, has a significant independent association with plasma XOR activity. In previous reports, HOMA-IR, calculated using fasting insulin and glucose levels, has been well established as a simple and excellent index for insulin resistance; thus, it is considered to represent that mainly in the liver in healthy, obese, and diabetic individuals with compensatory hyperinsulinemia [14, 15, 27, 28]. The present results indicate that insulin resistance, but not visceral adiposity or reduction in serum adiponectin, might be independently associated with increased XOR activity, thus suggesting that development of insulin resistance resulting from increased visceral adiposity and/or reduced serum adiponectin may contribute to hyperuricemia by stimulating XOR activity.

In mice, XOR is highly expressed in the liver, intestines, and visceral fat [29], whereas in humans, it is known to be expressed in the liver and intestines but not in visceral fat [7, 30]. Consistent with that basic understanding, in the present multiple regression analysis, VFA, VFA and SFA, and BMI were not independently associated with plasma XOR activity (Tables 2–4; Figure 2). In addition, our findings support those of a previous report in which change in body weight was found to be not correlated with change in plasma XOR activity during weight loss program in obese subjects, whereas that was decreased after weight loss in those subjects [31]. Notably, XOR activity in the liver, in contrast to that in the intestines, is not determined by primary or genetic factors in hyperuricemia patients [10], indicating that secondary factors affect that activity in the liver. In the present study, HOMA-IR was significantly and positively associated with plasma XOR activity, independent of VFA and adiponectin level (Table 2; Figures 1–3). A previous animal study showed that elevated insulin directly enhanced XOR activity in the liver [32]. Furthermore, insulin resistance is considered to increase ribose-5-phosphate production by impairing the glycolysis pathway through reduced glyceraldehyde-3-phosphate dehydrogenase activity [33] and increase adenosine triphosphate degradation to adenosine monophosphate [34], suggesting that insulin resistance indirectly activates XOR activity in the liver via enhanced purine degradation. A previous clinical study also found that plasma XOR activity was significantly decreased after administration of metformin in patients with diabetes [35]. Thus, insulin resistance or hyperinsulinemia might contribute to increased XOR activity in the liver via a complex pathway, resulting in increased production and reduced renal excretion of uric acid. Because insulin resistance is known to be caused in part by hypoadiponectinemia associated with visceral fat accumulation [36, 37], previous findings of the association of serum adiponectin and serum uric acid levels [38] might reflect an association of insulin resistance with XOR activity in the liver.

Other important findings obtained in the present study include the association of HbA1c and gender with plasma XOR activity (Table 2, Figure 4). Several studies have shown that moderate glycemic control status is associated with higher serum uric acid levels [39, 40]. Other groups have demonstrated that blood XOR activity is higher in patients with DM [41, 42], whereas glycemic control status was shown to be positively correlated with blood XOR activity in patients with DM [42] or cardiovascular disease [43]. Furthermore, we previously reported that plasma XOR activity was significantly higher in hemodialysis patients with DM as compared with those without DM, and there was a positive correlation of glycemic control status and plasma XOR activity in hemodialysis patients with DM [44]. Of importance, an in vitro study found that glucose increases uric acid production by hepatocytes [45], while another study demonstrated that streptozotocin-induced diabetic rats have increased XOR activity in the liver without the release of other hepatic enzymes such as alanine aminotransferase [46]. Thus, hyperglycemia might directly activate hepatic XOR activity, resulting in a higher level of uric acid in DM patients.

Consistent with previous studies [47, 48] that reported higher hepatic XOR activity in male subjects and rats as compared with female subjects, we noted that male subjects in the present study had a significantly and independently
higher level of plasma XOR activity than female subjects. Hepatic XOR activity is significantly increased after puberty, while it has been found to be significantly decreased following an orchietomy in male rats, and hepatic XOR activity was shown to be significantly increased after an ovariectomy and following administration of testosterone in female rats [47]. Importantly, the "sex×HOMA − IR" interaction was not significant in the present study, indicating that sex difference does not have an effect on the relationship between HOMA-IR and plasma XOR activity. Those previous studies along with the present results suggest that sex hormones modulate hepatic XOR activity, resulting in higher plasma XOR activity in male subjects as compared with female subjects, which may explain, at least in part, the generally higher uric acid level seen in male subjects.

In our previous study that also used the present MedCity21 health examination registry, we found that plasma XOR activity was positively and independently associated with serum uric acid level [18]. There are important differences between the present and that previous study. Although the final 200 sequential participants in the registry were selected and plasma XOR activity was measured using our novel highly sensitive assay in both, 2
Figure 3: Adiponectin and plasma XOR activity. Adiponectin level was not independently associated with plasma XOR activity. Point estimates and the 95% confidence interval for these relationships are shown by a solid line and gray band, respectively. Values for adiponectin and plasma XOR activity are expressed as μg/mL and pmol/h/mL, respectively. Log plasma XOR activity was adjusted to the median values for age (56 years), sex (female), alcohol drinking habit (absence), smoking habit (absence), ALT (17 U/L), HbA1c (5.7 %), eGFR (76.8 mL/min/1.73 m²), VFA (69.8 cm²), and log HOMA-IR (0.146).

Table 3: Multiple regression analysis of factors associated with plasma XOR activity including VFA and SFA.

| Independent variable | Percentile | Coefficient | 95% LCI | 95% UCI | p value | VIF |
|----------------------|------------|-------------|--------|--------|---------|-----|
|                      | 25th | 75th | Difference |       |         |      |
| Age                  | 47   | 67   | 0.052     | −0.026 | 0.130   | 0.192 | 1.668 |
| Sex (male = 1, female = 0) | 0   | 1    | 0.110     | 0.015  | 0.053   | 0.026  | 1.500 |
| Alcohol drinking habit (present = 1, absent = 0) | 0   | 1    | −0.065    | −0.155 | 0.025   | 0.154  | 1.225 |
| Smoking habit (present = 1, absent = 0) | 0   | 1    | 0.073     | −0.032 | 0.178   | 0.172  | 1.211 |
| ALT                  | 13.0 | 25.0 | 0.228     | 0.173  | 0.283   | 0.001  | 1.693 |
| HbA1c                | 5.5  | 6.0  | 0.058     | 0.006  | 0.109   | 0.028  | 1.466 |
| eGFR                 | 66.3 | 86.5 | 0.062     | −0.006 | 0.130   | 0.075  | 1.543 |
| VFA and SFA          | 153.7 | 265.1 | 0.027     | −0.050 | 0.104   | 0.498  | 2.535 |
| Log adiponectin      | 0.813 | 1.041 | −0.050    | −0.112 | 0.012   | 0.072  | 1.779 |
| Log HOMA-IR          | −0.46 | 0.322 | 0.108     | 0.030  | 0.185   | 0.021  | 2.344 |

Abbreviations: XOR, xanthine oxidoreductase; ALT, alanine aminotransferase; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; VFA, visceral fat area; SFA, subcutaneous fat area; HOMA-IR, homeostatic model assessment of insulin resistance; LCI, lower confidence interval; UCI, upper confidence interval; VIF, variance inflation factor.

Table 4: Multiple regression analysis of factors associated with plasma XOR activity including BMI.

| Independent variable | Percentile | Coefficient | 95% LCI | 95% UCI | p value | VIF |
|----------------------|------------|-------------|--------|--------|---------|-----|
|                      | 25th | 75th | Difference |       |         |      |
| Age                  | 47   | 67   | 0.057     | −0.021 | 0.134   | 0.154 | 1.686 |
| Sex (male = 1, female = 0) | 0   | 1    | 0.109     | 0.018  | 0.201   | 0.020  | 1.380 |
| Alcohol drinking habit (present = 1, absent = 0) | 0   | 1    | −0.064    | −0.154 | 0.026   | 0.161  | 1.223 |
| Smoking habit (present = 1, absent = 0) | 0   | 1    | 0.075     | −0.030 | 0.180   | 0.163  | 1.218 |
| ALT                  | 13.0 | 25.0 | 0.228     | 0.173  | 0.283   | 0.001  | 1.696 |
| HbA1c                | 5.5  | 6.0  | 0.054     | 0.003  | 0.105   | 0.038  | 1.462 |
| eGFR                 | 66.3 | 86.5 | 0.057     | −0.011 | 0.125   | 0.098  | 1.544 |
| BMI                  | 20.7 | 24.7 | −0.007    | −0.075 | 0.061   | 0.832  | 2.457 |
| Log adiponectin      | 0.813 | 1.041 | −0.062    | −0.122 | −0.003  | 0.054  | 1.726 |
| Log HOMA-IR          | −0.46 | 0.322 | 0.117     | 0.042  | 0.193   | 0.010  | 2.266 |

Abbreviations: XOR, xanthine oxidoreductase; ALT, alanine aminotransferase; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; LCI, lower confidence interval; UCI, upper confidence interval; VIF, variance inflation factor.
participants treated with a sodium-glucose cotransporter 2 inhibitor and included in the present study were excluded from our previous database used for analysis, in order to eliminate findings from subjects taking a drug that can have effects on serum uric acid level. In addition, plasma XOR activity was used as a covariate and serum uric acid level as an independent variable in multivariable linear regression analyses to examine the association of plasma XOR activity with serum uric acid in our previous study. On the other hand, HOMA-IR was used as a covariate and plasma XOR activity as an independent variable in multivariable linear regression analyses performed in the present study in order to examine the association of insulin resistance with plasma XOR activity. Thus, the purposes, methods, and results differ between these investigations.

This was a cross-sectional study, thus even though relationships were explored in predictive terms, the results cannot be interpreted to show causal relationships. From this present study, the possibility that increased XOR activity contributes to increased insulin resistance could not be denied. Therefore, a longitudinal study is necessary to clarify the role of insulin resistance in regard to XOR activity.

5. Conclusions

Our results showed that insulin resistance is associated with plasma XOR activity in a manner independent of visceral adiposity and adiponectin level. Furthermore, they suggest that development of insulin resistance caused by increased visceral adiposity and/or reduced serum adiponectin may contribute to increased uric acid production by stimulating XOR activity.

Data Availability

The data analyzed during the study are not publicly available, in order to protect patient privacy, as it might be possible to identify the results of an individual patient from this limited group of patients.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

The authors thank Ms. Maya Yoshida and Ms. Akane Utsunomiya for their assistance with the imaging procedures. This study was supported by a research grant from Sanwa Kagaku Kenkyusho and a grant-in-aid for scientific research from the Gout Research Foundation (both to M. K.). The funding bodies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

[1] J. Lee, D. Sparrow, P. S. Vokonas, L. Landsberg, and S. T. Weiss, “Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome,” American Journal of Epidemiology, vol. 142, no. 3, pp. 288–294, 1995.
[2] S. Takahashi, T. Yamamoto, Z. Tsutsumi, Y. Moriwaki, J. Yamakita, and K. Higashino, “Close correlation between visceral fat accumulation and uric acid metabolism in healthy men,” Metabolism, vol. 46, no. 10, pp. 1162–1165, 1997.
[3] H. Vuorinen-Markkola and H. Yki-Jarvinen, “Hyperuricemia and insulin resistance,” Journal of Clinical Endocrinology & Metabolism, vol. 78, no. 1, pp. 25–29, 1994.
[4] F. Facchini, Y. D. Chen, C. B. Hollenbeck, and G. M. Reaven, “Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration,” The Journal of the American Medical Association, vol. 266, no. 21, pp. 3008–3011, 1991.
[5] F. Matsuura, S. Yamashita, T. Nakamura et al., “Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity,” Metabolism, vol. 47, no. 8, pp. 929–933, 1998.
[6] R. Hille and T. Nishino, “Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase,” The FASEB Journal, vol. 9, no. 11, pp. 995–1003, 1995.
[7] T. A. Krenitsky, J. V. Tuttle, E. L. Cattau Jr., and P. Wang, “A comparison of the distribution and electron acceptor specificities of xanthine oxidase and aldehyde oxidase,” Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, vol. 49, no. 4, pp. 687–703, 1974.
[8] H. Nagao, H. Nishizawa, Y. Tanaka et al., “Hypoxanthine secretion from human adipose tissue and its increase in hypoxia,” Obesity, vol. 26, no. 7, pp. 1168–1178, 2018.
[9] H. K. Tam, A. S. Kelly, A. M. Metzig, J. Steinberger, and L. A. A. Johnson, “Xanthine oxidase and cardiovascular risk in
obese children,” *Childhood Obesity*, vol. 10, no. 2, pp. 175–180, 2014.

[10] R. Marcolongo, E. Marinello, G. Pompucci, and R. Pagani, “The role of xanthine oxidase in hyperuricemic states,” *Arthritis & Rheumatism*, vol. 17, no. 4, pp. 430–438, 1974.

[11] K. Washio, Y. Kusunoki, T. Murase et al., “Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans,” *Metabolism*, vol. 70, pp. 51–56, 2017.

[12] S. Martinez-Hervas, J. T. Real, C. Ivorra et al., “Increased plasma xanthine oxidase activity is related to nuclear factor kappa beta activation and inflammatory markers in familial combined hyperlipidemia,” *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 20, no. 10, pp. 734–739, 2010.

[13] M. Furuhashi, M. Matsumoto, M. Tanaka et al., “Plasma xanthine oxidoreductase activity as a novel biomarker of metabolic disorders in a general population,” *Circulation Journal*, vol. 82, no. 7, pp. 1892–1899, 2018.

[14] M. Emoto, Y. Nishizawa, K. Maekawa et al., “Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas,” *Diabetes Care*, vol. 22, no. 5, pp. 818–822, 1999.

[15] H. Yokoyama, M. Emoto, S. Fujiwara et al., “Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients,” *Diabetes Care*, vol. 26, no. 8, pp. 2426–2432, 2003.

[16] T. Murase, M. Nampei, M. Oka, A. Miyachi, and T. Nakamura, “A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS,” *Journal of Chromatography B*, vol. 1039, pp. 51–58, 2016.

[17] T. Murase, M. Oka, M. Nampei, A. Miyachi, and T. Nakamura, “A highly sensitive assay for xanthine oxidoreductase activity using a combination of [13C2, 15N2] xanthine and liquid chromatography/triple quadrupole mass spectrometry,” *Journal of Labelled Compounds and Radiochemicals*, vol. 59, no. 5, pp. 214–220, 2016.

[18] M. Kurahaj, S. Fukumoto, M. Emoto et al., “Independent association of plasma xanthine oxidoreductase activity with serum uric acid level based on stable isotope-labeled xanthine and liquid chromatography/triple quadrupole mass spectrometry: MedCity21 health examination registry,” *Clinical Chemistry and Laboratory Medicine*, 2019, In press.

[19] M. Hayashi, T. Morioka, M. Hatamori et al., “Plasma omentin levels are associated with vascular endothelial function in patients with type 2 diabetes at elevated cardiovascular risk,” *Diabetes Research and Clinical Practice*, vol. 148, pp. 160–168, 2019.

[20] F. Tanaka, S. Fukumoto, T. Morisaki et al., “Obesity and hiatal hernia may be non-allergic risk factors for esophageal eosinophilia in Japanese adults,” *Esophagus*, vol. 16, no. 3, pp. 309–315, 2019.

[21] American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” *Diabetes Care*, vol. 37, no. 1, pp. S81–S90, 2014.

[22] K. Shimamoto, K. Ando, T. Fujita et al., “Hypertension committee for guidelines for the management of, the Japanese society of hypertension guidelines for the management of hypertension (JSH 2014),” *Hypertension Research*, vol. 37, no. 4, pp. 253–390, 2014.

[23] T. Teramoto, J. Sasaki, S. Ishibashi et al., “Executive summary of the Japan atherosclerosis society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan–2012 version,” *Journal of Atherosclerosis and Thrombosis*, vol. 20, no. 6, pp. 517–523, 2013.

[24] S. Matsu, E. Imai, M. Horio et al., “Revised equations for estimated GFR from serum creatinine in Japan,” *American Journal of Kidney Diseases*, vol. 53, no. 6, pp. 982–992, 2009.

[25] The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes, Y. Seino, K. Nanjo et al., “Report of the committee on the classification and diagnostic criteria of diabetes mellitus,” *Journal of Diabetes Investigation*, vol. 1, no. 5, pp. 212–228, 2010.

[26] A. Nishimura and T. Sawai, “Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer,” *Clinica Chimica Acta*, vol. 371, no. 1–2, pp. 163–168, 2006.

[27] T. M. Wallace, J. C. Levy, and D. R. Matthews, “Use and abuse of HOMA modeling,” *Diabetes Care*, vol. 27, no. 6, pp. 1487–1495, 2004.

[28] D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” *Diabetologia*, vol. 28, no. 7, pp. 412–419, 1985.

[29] Y. Tsushima, H. Nishizawa, Y. Tsuchino et al., “Uric acid secretion from adipose tissue and its increase in obesity,” *Journal of Biological Chemistry*, vol. 288, no. 38, pp. 27138–27149, 2013.

[30] Y. Moriwaki, T. Yamamoto, M. Suda et al., “Purification and immunohistochemical tissue localization of human xanthine oxidase,” *Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular Enzymology*, vol. 1164, no. 3, pp. 327–330, 1993.

[31] H. K. Tam, A. S. Kelly, C. K. Fox, B. M. Nathan, and L. A. A. Johnson, “Weight loss mediated reduction in xanthine oxidase activity and uric acid clearance in adolescents with severe obesity,” *Childhood Obesity*, vol. 12, no. 4, pp. 286–291, 2016.

[32] J. M. Wu, J. S. Nickels, and J. R. Fisher, “Regulation of nitrogen catabolic enzymes in chick liver: effects of insulin,” *Enzyme*, vol. 22, no. 1, pp. 60–69, 1977.

[33] F. Leyva, C. S. Wingrove, I. F. Godsland, and J. C. Stevenson, “The glycolytic pathway to coronary heart disease: a hypothesis,” *Metabolism*, vol. 47, no. 6, pp. 657–662, 1998.

[34] J. Szendroedi, M. Chmelik, A. I. Schmid et al., “Abnormal hepatic energy homeostasis in type 2 diabetes,” *Hepatology*, vol. 50, no. 4, pp. 1079–1086, 2009.

[35] V. Cosic, S. Antic, M. Pesic, O. Jovanovic, S. Kundalic, and V. B. Djordjevic, “Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients?,” *Clinical Chemistry and Laboratory Medicine*, vol. 39, no. 9, pp. 818–821, 2001.

[36] T. Yatagai, S. Nagasaka, A. Taniguchi et al., “Hypo-adiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus,” *Metabolism*, vol. 52, no. 10, pp. 1274–1278, 2003.

[37] Y. Yamamoto, H. Hirose, I. Saito, K. Nishikai, and T. Saruta, “Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 89, no. 1, pp. 87–90, 2004.

[38] S. Tamba, H. Nishizawa, T. Funahashi et al., “Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men,” *Internal Medicine*, vol. 47, no. 13, pp. 1175–1180, 2008.
[39] J. Herman and U. Goldbourt, “Uric acid and diabetes: observations in a population study,” The Lancet, vol. 320, no. 8292, pp. 240–243, 1982.

[40] H. K. Choi and E. S. Ford, “Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels—the third National Health and Nutrition Examination Survey,” Rheumatology, vol. 47, no. 5, pp. 713–717, 2008.

[41] D. J. Miric, B. M. Kisic, S. Filipovic-Danic et al., “Xanthine oxidase activity in type 2 diabetes mellitus patients with and without diabetic peripheral neuropathy,” Journal of Diabetes Research, vol. 2016, Article ID 4370490, 2016.

[42] U. R. Kuppusamy, M. Indran, and P. Rokiah, “Glycaemic control in relation to xanthine oxidase and antioxidant indices in Malaysian type 2 diabetes patients,” Diabetic Medicine, vol. 22, no. 10, pp. 1343–1346, 2005.

[43] Y. Fujimura, Y. Yamauchi, T. Murase et al., “Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients,” PLoS One, vol. 12, no. 8, Article ID e0182699, 2017.

[44] A. Nakatani, S. Nakatani, E. Ishimura et al., “Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients,” Scientific Reports, vol. 7, no. 1, p. 15416, 2017.

[45] J. L. Petrie, G. L. Patman, I. Sinha, T. D. Alexander, H. L. Reeves, and L. Agius, “The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis,” American Journal of Physiology-Endocrinology and Metabolism, vol. 305, no. 10, pp. E1255–E1265, 2013.

[46] M.-C. Desco, M. Asensi, R. Marquez et al., “Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol,” Diabetes, vol. 51, no. 4, pp. 1118–1124, 2002.

[47] D. J. Levinson and D. Chalker, “Rat hepatic xanthine oxidase activity,” Arthritis & Rheumatism, vol. 23, no. 1, pp. 77–82, 1980.

[48] R. Guerciolini, C. Szumlanski, and R. M. Weinshilboum, “Human liver xanthine oxidase: nature and extent of individual variation,” Clinical Pharmacology and Therapeutics, vol. 50, no. 6, pp. 663–672, 1991.